A brief period of bumper profits for drugs manufacturers appears to be closing with the Covid-19 pandemic coming under control.
This content was published on
2 minutes
swissinfo.ch/mga
Pharmaceutical companies recorded a much lower return on their investment for producing medicines last year compared to 2021, according to a new study.
Consultancy firm Deloitte and the Centre for Health Solutions measured the cost of research and development (R&D) against drug sales among 20 of the world’s largest pharma companies.
In 2021, at the height of the pandemic, revenues outstripped R&D costs by 6.8%, but this figure fell to 1.2% last year.
Around half of this reduced return on investment was put down to decreasing demand for new Covid-19 drugs and treatments.
More
More
Looking ahead: Switzerland’s economic outlook for 2023
This content was published on
Our economic journalists outline the major developments awaiting the Swiss economy.
Other factors are inflation, logistics bottlenecks and the increasing length of time it takes to get some drugs onto the market.
As the pandemic put hospitals under pressure, global regulators allowed some treatments, including vaccines, to fast-track through the system.
But any hope of this trend continuing have been dashed. “The anticipated impact of Covid-19 on cycle time acceleration last year has not continued,” the report states.
The average development time for new drugs increased to 7.1 years in 2022 from 6.9 years in 2021. As a result, pharma firms expect the cost of producing new drugs to rise by $298 million to $2.3 billion (CHF2.1 billion).
Anticipated future peak sales for each new drug came down from $500 million in 2021 to $389 million last year. The 20 companies spent $139 billion on R&D in 2022, fractionally down from the previous year.
The report’s authors urged companies to improve their R&D process through digitisation.
They also warned that deteriorating political relations between Switzerland and the European Union could have an adverse impact on the Swiss pharma industry.
More
More
Swiss pharma giants fall in access to medicine ranking
This content was published on
Both Roche and Novartis have slipped in a ranking of the top 20 pharma companies’ efforts to expand access to medicines in poor countries.
What do you think Switzerland’s Alain Berset can bring to the Council of Europe?
The former interior minister is to become the first Swiss Secretary General of the Council of Europe – which issues should his five-year term focus on?
Norway holds Swiss investments worth over CHF35 billion
This content was published on
The Norwegian sovereign wealth fund holds investments in Switzerland worth CHF 35.5 billion ($39 billion), says Norges Bank CEO Nicolai Tangen.
Flooding of Rhone River causes severe road and rail traffic disruptions
This content was published on
Due to flooding in canton Valais, southern Switzerland, the A9 motorway between Sierre and Sion is closed. Traffic was also severely disrupted on the Simplon railway line.
Two dead after landslide hits southern Switzerland
This content was published on
After a landslide hit the Maggia Valley in canton Ticino, rescuers from Swiss Air-Rescue recovered two bodies on Sunday. One person is still missing.
Swiss beat Italians 2-0 to reach Euro football quarter-finals
This content was published on
Switzerland beat defending champions Italy in Berlin on Saturday night, justifying their status as the tournament's "secret" favourites.
Switzerland must urgently improve electricity distribution, says new sector boss
This content was published on
Switzerland needs to develop its electricity transmission and distribution network, says the new president of the Association of Swiss Electricity Companies, Martin Schwab.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss pharma giants fall in access to medicine ranking
This content was published on
Both Roche and Novartis have slipped in a ranking of the top 20 pharma companies’ efforts to expand access to medicines in poor countries.
This content was published on
Pharma companies are close to a cure for cancer, but will the hefty price tags make treatments unaffordable for most of the world?
Novartis seals deal to license high-priced cancer drug
This content was published on
Swiss pharma giant Novartis has finalised a deal to allow generic production of its patented drug nilotinib to treat chronic myeloid leukemia.
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.